Ondansetron as an Antiemetic Medication

Introduction to Ondansetron

• Ondansetron is a 5-HT3 receptor antagonist widely used as an antiemetic medication to prevent nausea and vomiting associated with various conditions, as stated by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 1, 2

FDA-Approved Indications

• The FDA approves ondansetron for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, moderately emetogenic cancer chemotherapy, radiotherapy, and postoperative nausea and/or vomiting, although the specific citation for this is ignored, it is supported by 1

Formulations and Administration

• Ondansetron is available in multiple formulations, including oral tablets, oral dissolving tablets, oral soluble films, and an injectable formulation for intravenous administration, according to the Journal of Clinical Oncology 1

Dosage for Chemotherapy-Induced Nausea and Vomiting

• For chemotherapy-induced nausea and vomiting, the recommended dosage is 8 mg oral twice daily or 8 mg oral dissolving tablet twice daily, or 8 mg or 0.15 mg/kg IV, as recommended by the American Society of Clinical Oncology 1

Side Effects and Warnings

• Common side effects of ondansetron include headache, constipation, diarrhea, and malaise/fatigue, although the specific citation for this is ignored, it is notable that ondansetron is generally well-tolerated compared to older antiemetics, with a lower incidence of sedation and extrapyramidal reactions, as stated in the context of 1